These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

407 related articles for article (PubMed ID: 3123078)

  • 21. In vitro activity of ciprofloxacin compared with other agents against recent hospital isolates.
    Rubinstein E; Mark Z; Samra Y; Alkan M; Berger S
    Chemioterapia; 1986 Apr; 5(2):75-82. PubMed ID: 2939966
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Comparative study of the effect of sisomicin and other aminoglycosides on the causative agents of surgical infection].
    Navashin PS
    Antibiotiki; 1982 Dec; 27(12):26-9. PubMed ID: 6819812
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antibiotic use in neonatal sepsis.
    Yurdakök M
    Turk J Pediatr; 1998; 40(1):17-33. PubMed ID: 9722468
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of ciprofloxacin's synergism with other agents by multiple in vitro methods.
    Moody JA; Gerding DN; Peterson LR
    Am J Med; 1987 Apr; 82(4A):44-54. PubMed ID: 3107380
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Meropenem Yearly Susceptibility Test Information Collection antimicrobial susceptibility program in Spain: a 5-year analysis.
    Pascual A; Perea E; Alvarez M; Casal M; Garcia de Lomas J; Garcia Rodríguez JA; Martin R; Soria G; Zapardiel J;
    Diagn Microbiol Infect Dis; 2007 Feb; 57(2):195-200. PubMed ID: 17052882
    [TBL] [Abstract][Full Text] [Related]  

  • 26. N-formimidoyl-thienamycin and norfloxacin against multiple-resistant Pseudomonas aeruginosa strains. Combined in vitro activity and comparison with 14 other antibiotics.
    Martino P; Venditti M; Valente B; Brandimarte C; Serra P
    Drugs Exp Clin Res; 1985; 11(4):247-51. PubMed ID: 3939121
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Comparative bactericidal activity of imipenem and other antibiotics against Pseudomonas aeruginosa].
    Thabaut A; Meyran M
    Pathol Biol (Paris); 1988 May; 36(5):472-6. PubMed ID: 3136428
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Antimicrobial activity of doripenem (S-4661): a global surveillance report (2003).
    Fritsche TR; Stilwell MG; Jones RN
    Clin Microbiol Infect; 2005 Dec; 11(12):974-84. PubMed ID: 16307551
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of the in vitro activity of 9 antimicrobials against bacterial strains isolated from patients in intensive care units in brazil: MYSTIC Antimicrobial Surveillance Program.
    Mendes C; Hsiung A; Kiffer C; Oplustil C; Sinto S; Mimica I; Zoccoli C;
    Braz J Infect Dis; 2000 Oct; 4(5):236-44. PubMed ID: 11063555
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activity of meropenem and comparators against Pseudomonas aeruginosa and Acinetobacter spp. isolated in the MYSTIC Program, 2002-2004.
    Unal S; Garcia-Rodriguez JA
    Diagn Microbiol Infect Dis; 2005 Dec; 53(4):265-71. PubMed ID: 16360550
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comparative in vitro activity of cefepime against nosocomial isolates.
    Sofianou D; Tsoulfa S; Kontodimou L; Polydorou F; Malaka E
    J Chemother; 1997 Oct; 9(5):341-6. PubMed ID: 9373789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antimicrobial activity of seven oral antibiotics against selected community- and hospital-acquired pathogens.
    Murray PR
    Clin Ther; 1991; 13(2):224-31. PubMed ID: 1863937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current status of aminoglycoside resistance in hospital Enterobacteriaceae].
    Ronco E; Migueres ML; Vacheron F; Guenounou M
    Pathol Biol (Paris); 1988 May; 36(5):430-4. PubMed ID: 3043339
    [TBL] [Abstract][Full Text] [Related]  

  • 34. In vitro activity of ciprofloxacin against aminoglycoside-sensitive and -resistant gram-negative rods.
    Speciale A; Blandino G; Pellegrino MB; Borghi P; Caccamo F
    Chemioterapia; 1986 Jun; 5(3):196-9. PubMed ID: 2941174
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro synergy studies with ciprofloxacin and selected beta-lactam agents and aminoglycosides against multidrug-resistant Pseudomonas aeruginosa.
    Meyer RD; Liu S
    Diagn Microbiol Infect Dis; 1988 Nov; 11(3):151-7. PubMed ID: 3149927
    [TBL] [Abstract][Full Text] [Related]  

  • 36. In vitro activity of PD 117596-2, a broad-spectrum difluoroquinolone.
    Neu HC; Chin NX
    Eur J Clin Microbiol Infect Dis; 1989 Jul; 8(7):644-50. PubMed ID: 2506029
    [TBL] [Abstract][Full Text] [Related]  

  • 37. In-vitro activity of meropenem against clinical isolates in a multicentre study in Italy.
    Schito GC; Sanna A; Chezzi C; Ravizzola G; Leone F; Molinari G; Menozzi MG; Pirali F
    J Antimicrob Chemother; 1989 Sep; 24 Suppl A():57-72. PubMed ID: 2681128
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ability of laboratories to detect emerging antimicrobial resistance in nosocomial pathogens: a survey of project ICARE laboratories.
    Steward CD; Wallace D; Hubert SK; Lawton R; Fridkin SK; Gaynes RP; McGowan JE; Tenover FC
    Diagn Microbiol Infect Dis; 2000 Sep; 38(1):59-67. PubMed ID: 11025185
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro studies of ciprofloxacin and survey of resistance patterns in current isolates.
    Fernandes CJ; Ackerman VP
    Diagn Microbiol Infect Dis; 1990; 13(2):79-91. PubMed ID: 2369816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The in-vitro activity of piperacillin/tazobactam, ciprofloxacin, ceftazidime and imipenem against multiple resistant gram-negative bacteria.
    Mehtar S; Drabu YJ; Blakemore PH
    J Antimicrob Chemother; 1990 Jun; 25(6):915-9. PubMed ID: 2164513
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.